84 related articles for article (PubMed ID: 24709081)
1. GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.
Ogata M; Iwasaki N; Ide R; Takizawa M; Uchigata Y
Biochem Biophys Res Commun; 2014 Apr; 447(1):133-8. PubMed ID: 24709081
[TBL] [Abstract][Full Text] [Related]
2. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 analog liraglutide enhances proinsulin processing in pancreatic β-cells via a PKA-dependent pathway.
Wang L; Liu Y; Yang J; Zhao H; Ke J; Tian Q; Zhang L; Wen J; Wei R; Hong T
Endocrinology; 2014 Oct; 155(10):3817-28. PubMed ID: 25051441
[TBL] [Abstract][Full Text] [Related]
4. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.
Luo X; Pan L; Nie A; Wang Q; Gu Y; Li F; Zhang H; Li W; Li X
J Diabetes; 2013 Dec; 5(4):421-8. PubMed ID: 23590680
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
Kumari P; Nakata M; Zhang BY; Otgon-Uul Z; Yada T
Biochem Biophys Res Commun; 2018 May; 499(3):618-625. PubMed ID: 29601817
[TBL] [Abstract][Full Text] [Related]
7. β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.
Gleizes C; Kreutter G; Abbas M; Kassem M; Constantinescu AA; Boisramé-Helms J; Yver B; Toti F; Kessler L
J Cell Mol Med; 2016 Feb; 20(2):231-42. PubMed ID: 26607759
[TBL] [Abstract][Full Text] [Related]
8. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.
Miao X; Gu Z; Liu Y; Jin M; Lu Y; Gong Y; Li L; Li C
Peptides; 2018 Feb; 100():127-139. PubMed ID: 28712893
[TBL] [Abstract][Full Text] [Related]
9. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
10. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
Tamura K; Minami K; Kudo M; Iemoto K; Takahashi H; Seino S
PLoS One; 2015; 10(5):e0126003. PubMed ID: 25938469
[TBL] [Abstract][Full Text] [Related]
12. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
13. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
Shao Y; Yuan G; Feng Y; Zhang J; Guo X
Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
[TBL] [Abstract][Full Text] [Related]
14. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T
Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712
[TBL] [Abstract][Full Text] [Related]
15. Clinical approaches to preserve beta-cell function in diabetes.
Wajchenberg BL
Adv Exp Med Biol; 2010; 654():515-35. PubMed ID: 20217513
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
Lampropoulou E; Lymperopoulou A; Charonis A
Metabolism; 2016 Jan; 65(1):7-15. PubMed ID: 26683792
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study.
Ciregia F; Giusti L; Ronci M; Bugliani M; Piga I; Pieroni L; Rossi C; Marchetti P; Urbani A; Lucacchini A
Mol Biosyst; 2015 Jun; 11(6):1696-707. PubMed ID: 25912719
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.
Schisano B; Harte AL; Lois K; Saravanan P; Al-Daghri N; Al-Attas O; Knudsen LB; McTernan PG; Ceriello A; Tripathi G
Regul Pept; 2012 Feb; 174(1-3):46-52. PubMed ID: 22120833
[TBL] [Abstract][Full Text] [Related]
19. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
Vilsbøll T; Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide protects against glucolipotoxicity-induced RIN-m5F β-cell apoptosis through restoration of PDX1 expression.
Kornelius E; Li HH; Peng CH; Yang YS; Chen WJ; Chang YZ; Bai YC; Liu S; Huang CN; Lin CL
J Cell Mol Med; 2019 Jan; 23(1):619-629. PubMed ID: 30353648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
